Leading players Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca, and Sanofi remain at the forefront of this transformation
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al
They are designed to facilitate the precise and painless delivery of therapeutic agents through the skin and other biological barriers
A lot of people dont bring up diarrhea on GLP-1 medications because they feel its awkward or think its just part of it. I make a point to ask, because bowel changes can signal dehydration, food triggers, or that the dose is moving too fast
In 2025, the company delivered a solid +8.56% YoY revenue growth, driven by its immunology portfolio: Skyrizi ($17.56B) continues to surge with strong uptake across psoriasis and IBD, Rinvoq ($8.3B) is expanding rapidly across multiple inflammatory conditions, while Humira ($4.54B) continues to decline following loss of exclusivity marking a clear shift toward newer growth assets